Southwest Securities's Science and Technology Innovation Board in Pharmaceutical Industry: FD Zhangjiang (1349.HK), an innovative pharmaceutical company characterized by photodynamic drugs.
The company is an innovative pharmaceutical company characterized by photodynamic drugs, with two photodynamic therapy drugs: Ella (aminolevulinic acid for topical use) and Fumeda (Hympofen for injection). As the first drug approved for the treatment of port wine stains in the world, Helmpofen is expected to make a further breakthrough if it can raise funds to complete its registration in the United States.
Source: The above information is fromSouthwest Securities, with source link: https://www.swsc.com.cn/. Please contact this company if full report is needed.